



Daré Bioscience, Inc. to Present an Overview of Novel Intra-Vaginal Ring (IVR) Technologies at the Partnership Opportunities in Drug Delivery (PODD) Meeting Held in Boston, MA October 17th – 18th

October 15, 2018

SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women's health-focused biopharmaceutical company, today announced it will be presenting scientific and technical details on its innovative intra-vaginal ring (IVR) technologies at the Partnership Opportunities in Drug Delivery (PODD) meeting being held on the 17th and 18th of October in Boston, Massachusetts. Daré's Chief Scientific Officer, David Friend, PhD, will deliver a presentation entitled "Optimizing Drug Delivery Through Novel Intra-Vaginal Ring (IVR) Technology" on Wednesday, October 17th as part of the Track 2B sessions.

"With eight potentially first-in-class women's health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate convenience for women. Vaginal drug delivery is often the optimum delivery approach to achieve these objectives, and IVR technology has become one of our preferred interventional platforms," said Sabrina Martucci Johnson, President & CEO of Daré Bioscience. "Our portfolio features innovative IVR technologies including our non-hormonal contraceptive Ovaprene[®], which we believe has the potential to disrupt the contraceptive landscape by providing protection for one month without the use hormones, and our suite of ethylene-vinyl acetate (EVA) matrixed IVRs that can provide flexibility in terms of drug loading, drug delivery, and modulation of release rates across a wide array of molecules, hormones, peptides and proteins, facilitating new indications and applications of the technology."

Daré's EVA IVR technology includes DARE-HRT1 for dual hormone replacement as a potential treatment for the vasomotor symptoms of menopause and DARE-FRT1 for vaginal progesterone delivery in support of fertility and the prevention of pre-term birth. In addition to its novel IVR technologies, Daré is developing a topical formulation of sildenafil, the active ingredient in Viagra[®], for the treatment of female sexual arousal disorder (FSAD) as well as a novel vaginal formulation of the selective estrogen receptor modulator (SERM) tamoxifen to address and alleviate the symptoms of vulvar vaginal atrophy (VVA) for women diagnosed with and treated for hormone-receptor-positive (HR+) breast cancer.

"We are excited to leverage this forum to showcase our IVR technology in addition to our broader portfolio of innovative women's healthcare product candidates," said Dr. David Friend. "At Daré, our development strategy is to identify, acquire and accelerate novel innovation that is capable of addressing persistent unmet needs in women's health and we believe our IVR technologies will enable us to deliver on that strategy across a range of indications and therapeutic targets."

Over the last several months Daré has built a robust pipeline of potentially first-in-class product candidates, including two clinical-stage development programs, Ovaprene[®] and Sildenafil Cream, 3.6%, as well as a number of preclinical candidates targeting unmet needs in menopause, vaginal health, fertility and pregnancy prevention.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive and sexual health. The company's mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.

Daré's product portfolio includes two potential first-in-class candidates currently in clinical development: Ovaprene[®], a non-hormonal, monthly contraceptive vaginal ring, and Sildenafil Cream, 3.6%, a potential treatment for female sexual arousal disorder utilizing the same active ingredient as Viagra[®]. To learn more about Daré's full portfolio of women's health products, and mission to deliver novel therapies for women, please visit www.darebioscience.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Ovaprene's potential to disrupt the contraceptive market, the flexibility that IVRs can provide, the ability of IVRs to facilitate new indications and applications of the technology, and to the ability of IVR technology to enable Daré to deliver on its development strategy. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, and other factors discussed in the "Risk Factors" section of Daré's Report on Form 10-K filed with the Securities and Exchange Commission on March 28, 2018. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Daré's reports to the Securities and Exchange Commission, including Daré's reports on Forms 10-Q, 8-K and 10-K. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. Daré specifically disclaims any obligation to update any forward-looking statements included in this press release.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:

Ami Bavishi

Burns McClellan

abavishi@burnsmc.com

212-213-0006

OR

Media on behalf of Daré Bioscience, Inc.:

Amanda Guisbond

Canale Communications

amanda@canalecomm.com

781-405-8775

Source: Daré Bioscience, Inc.



Source: Dare Bioscience, Inc.